Commercialization of TCR analysis services
First written in FY2016. 18 of 21 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「CPM has multiple technologies for immune response analysis, supports testing that complies with the "Reliability Standards for Application Data (Article 43 of the Enforcement Regulations for the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc.)," and also undertakes analysis testing for company-sponsored clinical trials.」
CPM continues to undertake analysis testing, including immune response analysis and TCR/BCR repertoire analysis. - FY2025RestatedAnnual report
「CPM has multiple technologies for immune response analysis, supports testing that complies with the "Reliability Standards for Application Data (Article 43 of the Enforcement Regulations for the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc.)," and also undertakes analysis testing for company-sponsored clinical trials.」
CPM continues to undertake analysis testing, including immune response analysis and TCR/BCR repertoire analysis. - FY2023-Q3RestatedAnnual report
「CPM has multiple technologies for immune response analysis, supports testing that complies with the "Reliability Standards for Application Data (Article 43 of the Enforcement Regulations for the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc.)," and also undertakes analysis testing for company-sponsored clinical trials.」
CPM continues to undertake analysis testing, including immune response analysis and TCR/BCR repertoire analysis. - FY2023-Q1RestatedAnnual report
「CPM has multiple technologies for immune response analysis, supports testing that complies with the "Reliability Standards for Application Data (Article 43 of the Enforcement Regulations for the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc.)," and also undertakes analysis testing for company-sponsored clinical trials.」
CPM continues to provide immune response analysis services, including TCR/BCR repertoire analysis. - FY2022-Q3RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2022-Q1RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2021-Q3RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2021-Q2RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2021-Q1RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2020-Q3RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2020-Q2RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2020-Q1RestatedAnnual report
「The company operates a business providing TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR repertoire analysis services to pharmaceutical companies, medical institutions, research institutions, and others. - FY2018RestatedAnnual report
「The company operates a business providing TCR/BCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others.」
The company continues to provide TCR/BCR analysis services and use them in the vaccine business. - FY2018-Q3RestatedAnnual report
「As an advanced initiative in cancer immunotherapy, the Group has introduced a method developed at the laboratory of Nakamura Yusuke (中村祐輔) at the University of Chicago Medical School for analyzing T-cell and B-cell receptors using next-generation sequencing. It operates a business providing TCR/BCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others, while advancing its vaccine business with an emphasis on scientific evidence.」
The company continues to provide TCR/BCR analysis services and use them in the vaccine business. - FY2018-Q2AdvancedAnnual report
「As of the date of submission of this document, the company had transferred its Tumor Immunology Analysis Department to CPM through a company split (simplified split). The department was a business division of the company engaged in research and development of cancer immunotherapies, including oncoantigens, and, as an advanced initiative, provided analysis services for T-cell and B-cell receptors using next-generation sequencing.」
The company transferred its Tumor Immunology Analysis Department, including the TCR/BCR analysis service, to CPM, establishing a concrete operating platform for the service business. - FY2018-Q1AdvancedAnnual report
「As an advanced initiative in cancer immunotherapy, we introduced a method developed at the laboratory of Nakamura Yusuke (中村祐輔) at the University of Chicago Medical School for analyzing T-cell and B-cell receptors using next-generation sequencing. We also began a business providing TCR/BCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others, while advancing our vaccine business with an emphasis on scientific evidence.」
The company expanded the scope of its services from TCR analysis to TCR/BCR analysis and continues to expand their use in cancer immunotherapy and the provision of these services. The transfer of the business to CPM also indicated expansion into a personalized medicine business, including clinical applications. - FY2017RestatedAnnual report
「We introduced a method for analyzing T-cell receptors using next-generation sequencing and began a business providing TCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others, while advancing our vaccine business with an emphasis on scientific evidence. We expect to expand the business, primarily among cancer researchers, through educational activities such as conference presentations and seminars.」
The company reiterates its policy of providing TCR analysis services, using them in the vaccine business, and expanding the business through conferences and seminars. - FY2017-Q3RestatedAnnual report
「We introduced a method for analyzing T-cell receptors using next-generation sequencing and began a business providing TCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others, while advancing our vaccine business with an emphasis on scientific evidence. We expect to expand the business, primarily among cancer researchers, through educational activities such as conference presentations and seminars.」
The company reiterates its policy of providing TCR analysis services, using them in the vaccine business, and expanding the business through conference presentations and seminars. - FY2017-Q2RestatedAnnual report
「We introduced a method for analyzing T-cell receptors using next-generation sequencing and began a business providing TCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others, while advancing our vaccine business with an emphasis on scientific evidence. We expect to expand the business, primarily among cancer researchers, through educational activities such as conference presentations and seminars.」
The company continues its policy of providing TCR analysis services and expanding the business through conference presentations and seminars. - FY2017-Q1RestatedAnnual report
「We introduced a method for analyzing T-cell receptors using next-generation sequencing and began a business providing TCR analysis services to pharmaceutical companies, medical institutions, research institutions, and others, while advancing our vaccine business with an emphasis on scientific evidence.」
The company continues to explain the launch of its TCR analysis service and its use in the vaccine business. - FY2016First statedAnnual report
「In September 2015, we began work on a T-cell receptor (TCR) analysis service, an advanced initiative in the field of cancer immunotherapy.」
The company introduced TCR analysis using next-generation sequencing and began offering contract services to pharmaceutical companies, medical institutions, and research institutions.